This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength in its Global Industrial segment.
Exact Sciences (EXAS) Stock Moves -1.09%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $67.82, moving -1.09% from the previous trading session.
Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
3 MedTech Stocks Likely to Beat Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.
Exact Sciences (EXAS) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $67.14, moving -0.46% from the previous trading session.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $66.21, moving -1.88% from the previous trading session.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $67.82 in the latest trading session, marking a -0.6% move from the prior day.
Exact Sciences (EXAS) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $67.92 in the latest trading session, marking a -0.67% move from the prior day.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
The Zacks Analyst Blog Highlights Jinko Solar, American Airlines and Exact Sciences
by Zacks Equity Research
Jinko Solar, American Airlines and Exact Sciences are included in this Analyst Blog.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $68.54 in the latest trading session, marking a +1.99% move from the prior day.
3 Top Stocks Already up More Than 20% In 2023
by Derek Lewis
While inflation remains the market's primary concern, these three stocks have gotten off to a great start in 2023, already up more than 20% year-to-date. Can the strength continue? Their earnings outlooks suggest so.
Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM
by Zacks Equity Research
EXAS, ZM, TSLA, ABBV, ZOM have been highlighted in this Market Edge article.
The Stocks Behind 2022's Popular ETFs
by Tracey Ryniec
What stocks do popular ETF managers like Cathie Wood own in their portfolios?